CLN

OZZIE GODINEZ, CEO & CO-FOUNDER OF PACO COLLECTIVE, WINS 2023 CLN LATINX ENTREPRENEUR AWARD

Retrieved on: 
Monday, October 16, 2023
Entrepreneurship, Learning, Contribution, CLN, Marketing, Ozzie, Fashion design

CHICAGO, Oct. 16, 2023 /PRNewswire/ -- Following a five-year hiatus, the Chicago Latino Network Awards UnGala returned this past Friday to celebrate the noteworthy achievements and work of Chicago's leading Latine leaders. From a field of prestigious nominees, PACO Collective's CEO, Ozzie Godinez, wins the CLN 2023 Latinx Entrepreneur Award.

Key Points: 
  • From a field of prestigious nominees, PACO Collective's CEO, Ozzie Godinez, wins the CLN 2023 Latinx Entrepreneur Award.
  • As CEO and Co-Founder, Ozzie has helped to guide the team to deliver innovative work that empowers and authentically represents today's ever-increasing diverse society.
  • The success of this work has allowed PACO to grow by 53% in staff since July 2021.
  • If interested in learning more about PACO Collective or engaging Ozzie Godinez in any speaking opportunities, please visit: https://pacocollective.com/contact-us/

EQS-News: ADM Energy PLC: Half-yearly Results

Retrieved on: 
Thursday, September 28, 2023
ADM, FPSO, Formerly Used Defense Sites, Midway-Sunset Oil Field, History, CLN, JV, Natural Resources, OFX, Acquisition, Investment, Nonformal learning, Blade, Chevron, Chevron Corporation, Environment, Risk management, Security (finance), Bank, Barracuda

In May 2023, ADM acquired Blade V from OFX Holdings LLC (Formerly TN Black Gold, LLC ("OFX") for a total maximum consideration of US$1,614,000.

Key Points: 
  • In May 2023, ADM acquired Blade V from OFX Holdings LLC (Formerly TN Black Gold, LLC ("OFX") for a total maximum consideration of US$1,614,000.
  • The Altoona Lease is a unique opportunity for ADM to benefit from substantial investment and de-risking of the target opportunities by a major company.
  • Stefan has extensive experience in the oil and gas sector, including as the co-founder of MX Oil plc, now ADM Energy.
  • These assets offer an exciting opportunity to add value, as well as diversifying the ADM portfolio.

KBRA Releases Research – RMBS Trend Watch: Slow and Steady 2023

Retrieved on: 
Thursday, May 18, 2023
Banking, Professional Services, Finance, KBRA, Projection, RMBS, Credit, FY, YTD, CLN, Cryptocurrency

KBRA releases its RMBS Trend Watch, providing updates on key RMBS market and performance themes as of year-to-date (YTD) 2023, as well as issuance volume trends and forecasts for 2023, collateral performance trends, and rating surveillance outcomes.

Key Points: 
  • KBRA releases its RMBS Trend Watch, providing updates on key RMBS market and performance themes as of year-to-date (YTD) 2023, as well as issuance volume trends and forecasts for 2023, collateral performance trends, and rating surveillance outcomes.
  • YTD 2023 Issuance Volume: While Q1 2023 issuance only came in at $13 billion, this exceeds our initial $7 billion projection made in November 2022.
  • 2023 Issuance Expectation: KBRA expects Q2 2023 volume to close at approximately $16 billion, and Q3 to remain roughly the same at $17 billion across RMBS 2.0.
  • Surveillance Activity: KBRA conducted surveillance reviews of 107 transactions as of May 15, 2023, resulting in 2,876 affirmations, 90 upgrades, and two downgrades.

Avextra AG Announces Closing of EU 17 Million Capital Raise

Retrieved on: 
Wednesday, March 15, 2023
Heart, Cannabis, IP, Growth, EU, CLN, Fine chemical, Pharmaceutical industry

Avextra announces the closing of its EU 17 Million Convertible Loan Note (“CLN”) bridge capital raise.

Key Points: 
  • Avextra announces the closing of its EU 17 Million Convertible Loan Note (“CLN”) bridge capital raise.
  • The CLN will automatically swap into equity at the next capital round currently in preparation.
  • Avextra cultivates proprietary genetics and runs an ambitious R&D program in Germany and Portugal.
  • BENSHEIM, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Avextra AG (“Avextra” or the “Company”), a leader in the European medical cannabis market, is proud to announce the closing of a EU 17 million capital raise with support from existing investors, the full management team and additional European investors.

Blockstream Raises USD $125M to Expand Mining Operations

Retrieved on: 
Tuesday, January 24, 2023
USD, Mining, ASIC, CFO, Miner, Core, Kingsway, Spondulix, Yoy, Acquisition, Risk, CLN, Cryptocurrency, Liquid, Blockstream, Carpe Fulgur, Bitcoin

MONTREAL, Jan. 24, 2023 /PRNewswire-PRWeb/ -- Leading Bitcoin infrastructure firm Blockstream has announced raising USD $125 million in convertible note and secured loan financing to expand its institutional bitcoin mining colocation services. Kingsway Capital led the convertible note, with other investors including Fulgur Ventures. Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC, is acting as exclusive financial advisor to Blockstream.

Key Points: 
  • MONTREAL, Jan. 24, 2023 /PRNewswire-PRWeb/ -- Leading Bitcoin infrastructure firm Blockstream has announced raising USD $125 million in convertible note and secured loan financing to expand its institutional bitcoin mining colocation services.
  • With over 500 Megawatts in its development pipeline, Blockstream is one of the world's largest bitcoin mining operators.
  • Blockstream will also expand its renewable energy mining products, and continue developing its own bitcoin miner - the first institutional-grade bitcoin miner purpose-built to scale.
  • Recent events in the broader cryptocurrency industry underscore the value and importance of the work Blockstream is doing in both blockchain development and bitcoin mining.

W.K. Kellogg Foundation Launches Global Fellows Network to Make Transformative Change for Children and Families

Retrieved on: 
Monday, November 14, 2022
W. K. Kellogg Foundation, WKKF, La June Montgomery Tabron, Fellows, Poverty, Work, Dream, Center, Creative Leadership, Multimedia, CLN, CEO, Life, GFN, Focus, Coffee, Solution, Drug, Online shopping, Management

BATTLE CREEK, Mich., Nov. 14, 2022 /PRNewswire/ -- Today the W.K. Kellogg Foundation (WKKF) announced the launch of its Global Fellows Network (GFN), a community of change agents, thought leaders and influencers from more than 40 countries who are working to transform systems, policies and practices that create conditions for thriving children, working families and equitable communities.

Key Points: 
  • Kellogg Foundation (WKKF) announced the launch of its Global Fellows Network (GFN), a community of change agents, thought leaders and influencers from more than 40 countries who are working to transform systems, policies and practices that create conditions for thriving children, working families and equitable communities.
  • The network is the living legacy of WKKF Founder Will Keith Kellogg who said, "I'll invest my money in people."
  • The Global Fellows Network will offer:
    Connectionbetween members and with the foundation to share ideas, resources and inspiration.
  • The Global Fellows Network includes leaders from 17 signature programs supported by WKKF since 1980; fellows who were part of those programs are encouraged to join the network.

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease

Retrieved on: 
Thursday, December 16, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, FFPM, European Commission, Survival, Disease, Mouse, Forward-looking statement, U.S. Securities and Exchange Commission, Glycogen storage disease, FDA, CLN, CTA, IND, AAV, Observational study, Serum, Quality of life, Drug development, Behavior, Development, Nasdaq, Severe cognitive impairment, COVID-19, SEC, CEO, DEM, Seizure, Prevalence, Associate, Dementia, Medical genetics, Natural history, Royal commission, MRCPCH, Food, MRCP, FRCPC, Death, Central nervous system, Life, CNS, Private Securities Litigation Reform Act, University, Annual report, Phenotype, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Department, CSF, Division, Gene, Pharmaceutical industry, Vaccine, Pediatrics, Research, PPT1, MBBS, CLN1, CLN1 Disease, Taysha Gene Therapies, CLN1 DISEASE, TAYSHA GENE THERAPIES

There is also an open investigational new drug application (IND) in the United States for TSHA-118 in CLN1 disease.

Key Points: 
  • There is also an open investigational new drug application (IND) in the United States for TSHA-118 in CLN1 disease.
  • Introduction of a functional CLN1 gene with TSHA-118 treatment offers a potentially effective therapeutic approach that addresses the root cause of the disease.
  • TSHA-118 is a self-complementary AAV9 gene replacement therapy designed to express a human codon-optimized CLN1 transgene for the treatment of CLN1 disease.
  • The global trial is a single arm, open-label Phase 1/2 trial evaluating TSHA-118 for the treatment of CLN1 disease utilizing commercial grade material.

Ziegler Closes $32,500,000 Financing For Christian Living Neighborhoods

Retrieved on: 
Tuesday, November 2, 2021
CFO, Housing, Industry, Public expenditure, Health, Private Securities Litigation Reform Act, Communication, CLN, Strategic planning, CLC, Company, News, Solution, Acquisition, Carney, Education, Survivor Series (2011), Security (finance), Management

CHICAGO, Nov. 2, 2021 /PRNewswire-PRWeb/ --Ziegler, a specialty investment bank, is pleased to announce the successful closing of Christian Living Neighborhoods' Series 2021 Bonds.

Key Points: 
  • CHICAGO, Nov. 2, 2021 /PRNewswire-PRWeb/ --Ziegler, a specialty investment bank, is pleased to announce the successful closing of Christian Living Neighborhoods' Series 2021 Bonds.
  • CLC owns and operates Christian Living Neighborhoods ("CLN") which is comprised of three separate and distinct communities in Colorado: Holly Creek, Someren Glen, and Clermont Park.
  • Christian Living Communities is ranked #96 on the 2020 LeadingAge Ziegler 200.
  • Will Carney, Managing Director, Ziegler Senior Living Finance added, "Christian Living Communities is a progressive senior living provider whose leadership team moved quickly to capture favorable market conditions and generate significant debt service savings.

Strateggyz - CLN Green in Paris

Retrieved on: 
Tuesday, October 12, 2021
Finance, Consulting, Environment, Professional Services, Other Professional Services, S&P Global, CDP, Translation, CDS, Credit default swap, MSCI, Risk, ISS, ESG, Sustainalytics, Network as a service, CLN, Security (finance), Bank

In October, Strateggyz launched its CLN Green activity on the Paris market.

Key Points: 
  • In October, Strateggyz launched its CLN Green activity on the Paris market.
  • Credit Linked Notes (CLN) are "synthetic bonds" issued by banks to transfer specific credit risks to investors.
  • A CLN is structured instrument using a derivative called a Credit Default Swap (CDS).
  • Above all, CLN Green is aimed at institutional investors and asset managers, who are looking to optimize their returns, better manage their risk and searching for a Green investment.

Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy

Retrieved on: 
Thursday, September 24, 2020
Branches of biology, Lipid storage disorders, Rare diseases, Articles, Biology, CLN6, Neurodegenerative disorders, Neuronal ceroid lipofuscinosis, Batten disease, Biotechnology, CLN, Infantile neuronal ceroid lipofuscinosis

CRANBURY, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to AT-GTX-501, the Companys investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis 6 (vLINCL6) disease, also known as CLN6 Batten disease.

Key Points: 
  • CRANBURY, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to AT-GTX-501, the Companys investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis 6 (vLINCL6) disease, also known as CLN6 Batten disease.
  • The PRIME designation is based on data from the ongoing Phase 1/2 clinical trial evaluating a single dose of AT-GTX-501 for the treatment of children with CLN6 Batten disease.
  • We are very pleased that the EMA has recognized the potential of our CLN6 gene therapy.
  • We look forward to continuing to work closely with the EMA to accelerate development of this first potential treatment option for children living with CLN6 Batten disease.